Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

PITTSBURGH, Oct. 26, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and nine months ended September 30, 2011.

Financial Highlights

  • Adjusted diluted EPS of $0.55 for the three months ended September 30 compared to $0.43 for the same prior year period;
  • Adjusted diluted EPS of $1.51 for the nine months ended September 30 compared to $1.16 for the same prior year period;
  • Total revenues of $1.58 billion for the three months ended September 30 compared to $1.36 billion for the same prior year period;  
  • Total revenues of $4.60 billion for the nine months ended September 30 compared to $4.02 billion for the same prior year period;  
  • On a GAAP basis, diluted EPS of $0.36 for the three months ended September 30 compared to $0.33 for the same prior year period;
  • On a GAAP basis, diluted EPS of $0.92 for the nine months ended September 30 compared to $0.71 for the same prior year period;
  • Cash provided by operating activities, excluding certain items, was $378.1 million, the highest quarter in terms of the generation of operating cash in the Company's history.

  • Mylan Chairman and CEO Robert J. Coury said: "We have once again delivered a quarter of strong top-line and bottom-line growth, a continued testament to the scale and diversity of our powerful global platform. I would like to note in particular the very impressive results of our specialty segment, Dey Pharma. As a result of strong execution across this business, Dey's performance is accelerating and it continues to be an important and exciting asset and growth driver for Mylan—one which we will continue to build on in the future."

    Coury continued: "We continually demonstrate that Mylan is much more than any one product or any single geography and have repeatedly absorbed the volatility
    '/>"/>

    SOURCE Mylan Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related biology technology :

    1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
    2. Life Technologies Announces Third Quarter 2011 Results
    3. Insmed to Host 2011 Third Quarter Earnings Conference Call
    4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
    5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
    6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
    7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
    8. HeartWare Schedules Third Quarter Conference Call and Webcast
    9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
    10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
    11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Read complete report with ...
    (Date:7/30/2014)... 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... 180 List of Outstanding Issues (LOI) from the European ... (CHMP) for the NB32 Marketing Authorization Application (MAA). NB32 ... investigational drug candidate being evaluated for weight loss. ... time point were adequately addressed by the Company based ...
    (Date:7/30/2014)... July 30, 2014  RXi Pharmaceuticals Corporation ... company focused on discovering, developing and commercializing ... using RNA-targeted technologies, today announced that their ... for the reduction of recurrence of hypertrophic ... been initiated. Logo - ...
    (Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
    Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
    ... 8, 2010 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... nanotechnology company developing products and licensing opportunities in ... and biotechnology research and development tools businesses, announced ... development and manufacturing agreement with EV Group, a ...
    ... properties, carbon nanotubes are attractive building blocks ... logic devices, and memory elements. However, ... of individual carbon nanotubes and the nanotube-devices, ... commercial use. Now, researchers at Northwestern ...
    ... Calif., Dec. 7, 2010 California-based StemCyte, Inc. ... www.StemCyte.com , a comprehensive resource on cord blood ... an effort to provide the most comprehensive source ... StemCyte,s new website includes extensive information for customers, ...
    Cached Biology Technology:Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 2Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 3Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 4Shrink Nanotechnologies' Shrink Chips Cell Culturing Unit Enters Into Exclusive Development and Manufacturing Agreement with EV Group to Commercialize the StemDisc Platform 5Using new materials to make more reliable nanoelectromechanical systems 2StemCyte Launches New Website 2
    (Date:7/30/2014)... massive collection of 20-million-year-old amber found in the Dominican ... is yielding fresh insights into ancient tropical insects and ... fully curated, a task that will take many years, ... in the world, the researchers report. , Perhaps ... a pygmy locust, a tiny grasshopper the size of ...
    (Date:7/30/2014)... use of iodine-125 (125I) in cancer treatment has ... root ganglia are critical for neural transmission between ... Zhang and colleagues from Institute of Radiation Medicine, ... 125I could be implanted into rat dorsal root ... 125I seeds with different radioactivity (0, 14.8, 29.6 ...
    (Date:7/30/2014)... map of the carbon stocks stored on land ... and improved methodology used to make the map ... economies. The new carbon map also reveals ... the critical input to studies of deforestation and ... purposes. The technique includes the determination of uncertainty ...
    Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3
    ... NEW YORK (July 24, 2009) -- A large attack on ... than a million people, necessitating their treatment with powerful antibiotics. ... to be effective, quick detection and treatment are essential, and ... ill people. The results of a computer simulation study ...
    ... GALVESTON, Texas Researchers at the University of Texas ... to gain weight while using depot medroxyprogesterone acetate, more commonly ... dispel the myth that all women who use DMPA will ... DMPA users whose weight increased by 5 percent within ...
    ... Union for the Conservation of Nature (IUCN),s Red List ... of species around the planet, and according to these ... endangered. However, research carried out recently by Jos Luis ... scientific protocol designed to identify threatened plants and animals. ...
    Cached Biology News:Early detection and quick response are key to defense against anthrax attack 2UTMB study identifies women at risk of gaining excessive weight with injectable birth control 2Red List overlooks island species 2Red List overlooks island species 3
    Applications: Western blotting ...
    Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
    Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
    ... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
    Biology Products: